Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

Marcos de Lima; Daniel Couriel; Peter F Thall; Xuemei Wang; Timothy Madden; Roy Jones; Elizabeth J Shpall; Munir Shahjahan; Betty Pierre; Sergio Giralt

doi:10.1182/blood-2004-02-0414

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

Identifier:nobleid.org/w1/20260515/CD0BDFB4

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/CD0BDFB4.svg?ark=w1%2F20260515%2FCD0BDFB4)](https://nobleid.org/work/w1/20260515/CD0BDFB4)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

Identifier:nobleid.org/w1/20260515/CD0BDFB4

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/CD0BDFB4.svg?ark=w1%2F20260515%2FCD0BDFB4)](https://nobleid.org/work/w1/20260515/CD0BDFB4)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work